PRIMARY STUDY

Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria

Key Findings:  Aliskiren, a direct renin inhibitor, given to subjects with chronic renal failure already taking olmesartan, an angiotensin II receptor antagonist, resulted in decreased urinary L-fatty acid binding protein (L-FABP) level by reducing proteinuria. This combination could help prevent the progression of kidney disease, renal injury, and inflammation.